Dimension Therapeutics Lands $30,000,000 New Funding

  • Feed Type
  • Date
    6/23/2014
  • Company Name
    Dimension Therapeutics
  • Mailing Address
    850 Memorial Drive 4th Floor Cambridge, MA 02139 USA
  • Company Description
    Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. The company was launched in 2013 by Fidelity Biosciences and REGENX Biosciences. Dimension has now raised $30M with funding from Fidelity Biosciences and OrbiMed. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. We are focused on advancing our platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics across a wide array of single-gene rare diseases.
  • Website
    http://www.dimensiontx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Rishi and the OrbiMed team will be valuable partners and strategic advisors as we continue to advance our novel gene therapy programs for patients with rare diseases.
  • M&A Terms
  • Venture Investor
  • Venture Investor

Trending on Xconomy